In this connection, the repression of the immune checkpoint inhibitor CTLA-4 by DNA methylation in ALCL can provide appropriate justification for the epigenetic therapy with the objective of re-sensitizing lymphoma cells to checkpoint regulation [62]. The gene discussed is CTLA4; the disease is lymphoma.